Moreover, FABP4 inhibition by HTS01037 attenuated the pro-inflammatory profile in macrophages [120], supporting the use of FABP4 inhibitors not only for the fatty liver, but also for the treatment of MASH. This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatohepatitis.